as 06-20-2025 4:00pm EST
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | BOSTON |
Market Cap: | 599.7M | IPO Year: | 2020 |
Target Price: | $114.73 | AVG Volume (30 days): | 279.7K |
Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -10.79 | EPS Growth: | N/A |
52 Week Low/High: | $26.70 - $91.83 | Next Earning Date: | 08-12-2025 |
Revenue: | $8,122,000 | Revenue Growth: | 270.02% |
Revenue Growth (this year): | -96.42% | Revenue Growth (next year): | 6358.50% |
PRAX Breaking Stock News: Dive into PRAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
Energy Global
17 days ago
GlobeNewswire
17 days ago
PR Newswire
17 days ago
GlobeNewswire
17 days ago
Business Wire
17 days ago
PR Newswire
17 days ago
Retail Banker International
17 days ago
The information presented on this page, "PRAX Praxis Precision Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.